Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs McCormick & Company, Incorporated — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B). The key difference: Halozyme Therapeutics Inc. Common Stock and McCormick & Company, Incorporated are close in size by market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and McCormick & Company, Incorporated for 67 Days on average.
| HALO | MKC | |
|---|---|---|
Market Cap | $12.58B | $12.39B |
Volume | 2,179,278 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $115.22 | $71.65 |
52-Week Low | $61.63 | $44.14 |
Typical Hold Time | 1 Days | 67 Days |
Enterprise Value | $14.49B | $17.07B |
Dividend Yield | — | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
McCormick (MKC) trades at $44.81, down 0.97% on the day, with a bearish technical signal and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $0.86, driven by margin expansion and the McCormick de Mexico acquisition. Revenue grew 17% in constant currency, and the full-year outlook was reaffirmed. Valuation ratios appear attractive with a P/E of 8.31 and net income margin of 19.39%, while cash flow trends show improvement in 2026.
The outlook is mixed; fundamentals are solid with earnings beats and dividend growth, but technicals and analyst sentiment lean cautious. Upside exists if execution continues, yet risks include integration challenges and macroeconomic pressures. The consensus price target of $53.50 implies potential appreciation, but near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
